Adma Biologics (ADMA) Common Equity (2011 - 2025)
Adma Biologics posted quarterly Common Equity of $477.3 million for Q4 2025, up 36.76% year-on-year from $349.0 million in Q4 2024, and up 10.7% on a QoQ basis from $431.2 million in Q3 2025.
Adma Biologics (ADMA) has 15 years of Common Equity data on file, last reported at $477.3 million in Q4 2025.
- For the quarter ending Q4 2025, Common Equity rose 36.76% year-over-year to $477.3 million; the trailing twelve-month figure through Dec 2025 stood at $477.3 million (up 36.76% YoY), and the FY2025 full-year result was $477.3 million, up 36.76% from the prior year.
- Common Equity for Q4 2025 stood at $477.3 million, up from $431.2 million in the prior quarter.
- Across five years, Common Equity topped out at $477.3 million in Q4 2025 and bottomed at $100.4 million in Q3 2022.
- The 5-year median for Common Equity is $149.1 million (2023), against an average of $207.2 million.
- The widest annual swing landed in 2023, when Common Equity declined 11.03%; it then soared 158.14% in 2024.
- A 5-year view of Common Equity shows it stood at $141.2 million in 2021, then gained by 7.65% to $152.0 million in 2022, then decreased by 11.03% to $135.2 million in 2023, then jumped by 158.14% to $349.0 million in 2024, then surged by 36.76% to $477.3 million in 2025.
- The last three Common Equity figures came in at $477.3 million (Q4 2025), $431.2 million (Q3 2025), and $398.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Adma Biologics | 1.90 Bn | 1.81 Bn | 88.82 Mn | 477.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 477.32 Mn |
| Sep 30, 2025 | 431.19 Mn |
| Jun 30, 2025 | 398.33 Mn |
| Mar 31, 2025 | 373.42 Mn |
| Dec 31, 2024 | 349.02 Mn |
| Sep 30, 2024 | 231.89 Mn |
| Jun 30, 2024 | 188.27 Mn |
| Mar 31, 2024 | 153.71 Mn |
| Dec 31, 2023 | 135.21 Mn |
| Sep 30, 2023 | 151.44 Mn |
| Jun 30, 2023 | 146.76 Mn |
| Mar 31, 2023 | 145.66 Mn |
| Dec 31, 2022 | 151.97 Mn |
| Sep 30, 2022 | 100.38 Mn |
| Jun 30, 2022 | 114.40 Mn |
| Mar 31, 2022 | 126.93 Mn |
| Dec 31, 2021 | 141.17 Mn |
| Sep 30, 2021 | 102.78 Mn |
| Jun 30, 2021 | 111.59 Mn |
| Mar 31, 2021 | 112.50 Mn |
| Dec 31, 2020 | 88.25 Mn |
| Sep 30, 2020 | 71.38 Mn |
| Jun 30, 2020 | 76.88 Mn |
| Mar 31, 2020 | 96.34 Mn |
| Dec 31, 2019 | 26.19 Mn |
| Sep 30, 2019 | 36.12 Mn |
| Jun 30, 2019 | 46.91 Mn |
| Mar 31, 2019 | 10.04 Mn |
| Dec 31, 2018 | 19.77 Mn |
| Sep 30, 2018 | 37.21 Mn |
| Jun 30, 2018 | 51.76 Mn |
| Mar 31, 2018 | 23.03 Mn |
| Dec 31, 2017 | 40.33 Mn |
| Sep 30, 2017 | 12.99 Mn |
| Jun 30, 2017 | 27.68 Mn |
| Mar 31, 2017 | -10.76 Mn |
| Dec 31, 2016 | -4.46 Mn |
| Dec 31, 2015 | 820,974.00 |
| Dec 31, 2014 | 6.01 Mn |
| Mar 31, 2013 | 6.40 Mn |
| Dec 31, 2012 | 9.42 Mn |
| Sep 30, 2012 | 11.61 Mn |
| Jun 30, 2012 | 14.66 Mn |
| Mar 31, 2012 | 15.75 Mn |
| Dec 31, 2011 | 385,816.00 |
| Sep 30, 2011 | -3,900.00 |
| Jun 30, 2011 | -1,306.00 |